Potential depressive central nervous system effects of brimonidine topical gel
Year: 2020
Type: article
Abstract: Brimonidine 0.33% topical gel is a Food and Drug Administration–approved treatment for rosacea that acts as an α2a-adrenergic agonist on cutaneous vessels, resulting in vasoconstriction.1 Within the central nervous system, stimulation of these receptors has the opposite effect, inhibiting adrenergic neurotransmission and resulting in central nervous system depression.2 Although its clinical use is to act at the peripheral α2a-adrenergic receptors, its highly lipophilic nature may allow it to act at inner central nervous system α2a-receptors, resulting in depressive effects.
Source: JAAD Case Reports
Authors: Cristina Foschi, Elizabeth Damstetter
Institutions: Rush University Medical Center, Rush University
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $600
OpenAlex ID: W3045767553
